Acer Therapeutics Inc.

Focused on the acquisition, development & commercialization of therapies for serious rare and life-threatening disease.

Founded 2013

Newton, United States 16 employees Post-IPO Debt Total: $116.95M Biotechnology, Health and Wellness +1

Acer Therapeutics Inc. is a biotechnology and pharmaceutical company founded in 2013 with the slogan "Focused on the acquisition, development & commercialization of therapies for serious rare and life-threatening diseases." The company is based in the United States. Acer's pipeline consists of four programs, including ACER-001 for treating inborn errors of metabolism, emetine hydrochloride for infectious diseases such as COVID-19, EDSIVO™ for vascular Ehlers-Danlos syndrome, and osanetant for induced Vasomotor Symptoms. Acer is led by a management team experienced in rare disease therapeutics, aiming for time and cost-efficient drug development to deliver safe and effective therapies urgently. Despite challenges, Acer has received a $1.00M Post-IPO Debt investment as of 26 June 2023. The company emphasizes its commitment to creating and maintaining an environment that values individual rights, hard work, fosters creativity, and promotes success. Acer is fueled by the talent and expertise of its employees, driven by the commitment to treating patients with critical unmet medical needs. The company's approach to drug development presents comparatively de-risked profiles, attributing to favorable safety, clinical proof-of-concept data, and accelerated paths for development, recognized by specific programs and procedures established by the FDA.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	$1.00M	-		26 Jun 2023
Post IPO Equity	$1.50M	-		30 Nov 2022
Post IPO Debt	$48.50M	2	Marathon Fund, SWK Holdings	07 Mar 2022
Post IPO Equity	$40.00M	-		01 Aug 2018
Post IPO Equity	$15.70M	1	TVM Capital Life Science	19 Sep 2017
Post IPO Equity	$8.15M	1	TVM Capital Life Science	06 May 2016
Post IPO Debt	$2.10M	-		02 Apr 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Debt

$1.00M

26 Jun 2023

Post IPO Equity

$1.50M

30 Nov 2022

Post IPO Debt

$48.50M

Marathon Fund, SWK Holdings

07 Mar 2022

Post IPO Equity

$40.00M

01 Aug 2018

Post IPO Equity

$15.70M

TVM Capital Life Science

19 Sep 2017

Post IPO Equity

$8.15M

TVM Capital Life Science

06 May 2016

Post IPO Debt

$2.10M

02 Apr 2015

FAQ About Acer Therapeutics Inc.

Focused on the acquisition, development & commercialization of therapies for serious rare and life-threatening disease.

Acer Therapeutics Inc. was founded in 2013.

Acer Therapeutics Inc. is headquartered in Newton, United States.

Acer Therapeutics Inc. operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on pharmaceutical company, rare diseases, drug development and therapeutic acquisition.

Acer Therapeutics Inc. has approximately 16 employees.

Acer Therapeutics Inc. has completed 7 funding rounds, raising a total of $116.95M. The latest funding stage is Post-IPO Debt.

Top alternatives and competitors to Acer Therapeutics Inc. include AMO Pharma LTD, Esperion, AN2 Therapeutics, Scioderm, Inc., an Amicus Therapeutics Company, AllStripes (now PicnicHealth). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Acer Therapeutics Inc. and AMO Pharma LTD are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Acer Therapeutics Inc.

Funding Rounds & Investors (7)

Acer Therapeutics Inc. Alternatives & Competitors

FAQ About Acer Therapeutics Inc.